322 related articles for article (PubMed ID: 26033641)
1. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
[TBL] [Abstract][Full Text] [Related]
2. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
4. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
[TBL] [Abstract][Full Text] [Related]
5. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
6. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
7. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
[TBL] [Abstract][Full Text] [Related]
8. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
O'Donoghue ML; Glaser R; Cavender MA; Aylward PE; Bonaca MP; Budaj A; Davies RY; Dellborg M; Fox KA; Gutierrez JA; Hamm C; Kiss RG; Kovar F; Kuder JF; Im KA; Lepore JJ; Lopez-Sendon JL; Ophuis TO; Parkhomenko A; Shannon JB; Spinar J; Tanguay JF; Ruda M; Steg PG; Theroux P; Wiviott SD; Laws I; Sabatine MS; Morrow DA;
JAMA; 2016 Apr; 315(15):1591-9. PubMed ID: 27043082
[TBL] [Abstract][Full Text] [Related]
9. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
Lomas DA; Lipson DA; Miller BE; Willits L; Keene O; Barnacle H; Barnes NC; Tal-Singer R;
J Clin Pharmacol; 2012 Mar; 52(3):416-24. PubMed ID: 22090363
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Yang S; Lukey P; Beerahee M; Hoke F
Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
[TBL] [Abstract][Full Text] [Related]
11. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
12. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
Ostenfeld T; Krishen A; Lai RY; Bullman J; Baines AJ; Green J; Anand P; Kelly M
Eur J Pain; 2013 Jul; 17(6):844-57. PubMed ID: 23239139
[TBL] [Abstract][Full Text] [Related]
13. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
14. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.
Vedel-Krogh S; Nielsen SF; Lange P; Vestbo J; Nordestgaard BG
Am J Respir Crit Care Med; 2016 May; 193(9):965-74. PubMed ID: 26641631
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
Ostenfeld T; Krishen A; Lai RY; Bullman J; Green J; Anand P; Scholz J; Kelly M
Clin J Pain; 2015 Apr; 31(4):283-93. PubMed ID: 25751578
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
17. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
Thompson WH; Carvalho P; Souza JP; Charan NB
Lung; 2002; 180(4):191-201. PubMed ID: 12391509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
